newsfilter
← Latest News
GlobeNewswire·

AVEO Oncology Reports First Quarter 2022 Financial Results

– Total Q1 2022 Net Revenue of $20.9 Million including $20.1 Million ofFOTIVDA® (tivozanib) U.S. Net Product Revenue – – Q1 2022 FOTIVDA Prescriptions Increased by 25% Compared With Q4 2021 – – Company Reaffirms Full Year 2022 FOTIVDA U